New pill could melt away heart disease plaque, major trial underway
NCT ID NCT06305559
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill (obicetrapib plus ezetimibe) to see if it can reduce fatty plaque buildup in the arteries of 300 adults with heart disease. Participants must already be on cholesterol-lowering therapy but still have high LDL cholesterol and measurable plaque. The trial uses CT scans to track plaque changes over 18 months, comparing the drug to a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NGMR
Hialeah, Florida, 33016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?
- Can a higher dose of adenosine sharpen heart scans?